3T非直肠内线圈前列腺磁共振在前列腺癌主动监测中的整合与诊断准确性
本研究回顾性纳入两家机构286例接受主动监测的Gleason 6前列腺癌患者,评估3T非直肠内线圈多参数前列腺磁共振的整合情况与诊断准确性。结果显示,PI-RADS v2评分1-2者87%未立即活检或治疗并继续主动监测,PI-RADS 3、4、5的阳性预测值分别为21%、51%、71%,且PI-RADS 1-3者未发现Gleason ≥4+3前列腺癌。结论认为该检查已整合入主动监测患者的管理,并能有效分层Gleason ≥3+4前列腺癌风险。
要点
- PI-RADS v2评分1-2者87%未立即活检或治疗并继续主动监测。
- PI-RADS 3、4、5的阳性预测值分别为21%、51%、71%。
- PI-RADS 1-3者未发现Gleason ≥4+3前列腺癌。
核心结论
- 3T非直肠内线圈mpMRI已整合入主动监测患者的管理,并能有效分层Gleason ≥3+4前列腺癌风险。
研究设计与样本
- 这是一项经机构审查委员会批准、符合健康保险流通与责任法案的双机构回顾性队列研究。
- 研究纳入13个月期间(2015年8月1日至2016年8月31日)在两机构接受3T非直肠内线圈mpMRI、符合预设标准(临床T1/T2 Gleason 6前列腺癌、PSA<15 ng/mL、≥40岁、活检后2年内行mpMRI、PI-RADS v2评分)的286例患者(机构1共193例,机构2共93例)。
- 排除因Gleason ≥3+4前列腺癌接受监测者;主要结局为mpMRI后6个月内经磁共振-超声融合活检、标准活检或前列腺切除术检出Gleason ≥3+4前列腺癌。
主要发现
- 最大PI-RADS v2评分为1-2的104例中,87%(90/104)未接受立即活检或治疗并继续主动监测。
- PI-RADS 3者57例(20%),阳性预测值21%(6/29);PI-RADS 4者96例(34%),阳性预测值51%(39/77);PI-RADS 5者29例(13%),阳性预测值71%(20/28)。
- PI-RADS v2评分1-3且有组织学结果的43例中,未发现Gleason ≥4+3前列腺癌(0/43)。
- mpMRI及后续活检后,21%(61/286)的受试者退出主动监测并接受根治性治疗。
关键数值与推荐
- PI-RADS v2评分≥3的阳性预测值:PI-RADS 3为21%(6/29),PI-RADS 4为51%(39/77),PI-RADS 5为71%(20/28)。
- PI-RADS v2评分1-2者中87%(90/104)未立即活检或治疗并继续主动监测。
- PI-RADS v2评分1-3且有组织学结果者中Gleason ≥4+3前列腺癌检出为0/43。
临床怎么用
- 在主动监测患者中,3T非直肠内线圈mpMRI的PI-RADS v2评分可用于分层Gleason ≥3+4前列腺癌风险,评分1-2者多可继续监测,评分≥3者需结合阳性预测值决定是否活检。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the integration of 3T nonendorectal coil multiparametric prostate magnetic resonance imaging (mpMRI) at 2 high-volume practices that routinely use mpMRI in the setting of active surveillance. MATERIALS AND METHODS: This was an institutional review board-approved, Health Insurance Portability and Accountability Act-compliant, and dual-institution retrospective cohort study. Subjects undergoing 3T mpMRI without endorectal coil at either study institution over a 13-month period (August 1, 2015-August 31, 2016) were selected based on predefined criteria: clinical T1/T2 Gleason 6 prostate cancer, prostate-specific antigen <15 ng/mL, ≥40 years old, mpMRI within 2 years of prostate biopsy, and Prostate Imaging Reporting and Data System (PI-RADS) v2 score assigned. Subjects surveilled for Gleason ≥3 + 4 prostate cancer were excluded. The primary outcome was detection of Gleason ≥3 + 4 prostate cancer on magnetic resonance-ultrasound fusion biopsy, standard biopsy, or prostatectomy within 6 months following mpMRI. Positive predictive values (PPVs) were calculated. RESULTS: A total of 286 subjects (N = 193 from institution 1, N = 93 from institution 2) met the criteria. Most (87% [90 of 104]) with maximum PI-RADS v2 scores of 1-2 did not receive immediate biopsy or treatment and remained on active surveillance. Incidence and PPVs for PI-RADS v2 scores of ≥3 were the following: PI-RADS 3 (n = 57 [20%], PPV 21% [6 of 29]), PI-RADS 4 (n = 96 [34%], PPV 51% [39 of 77]), and PI-RADS 5 (n = 29 [13%], PPV 71% [20 of 28]). No Gleason ≥4 + 3 prostate cancer was identified for PI-RADS v2 scores of 1-3 (0 of 43 with histology). Following mpMRI and subsequent biopsy, 21% (61 of 286) of subjects were removed from active surveillance and underwent definitive therapy. CONCLUSION: The 3T nonendorectal coil mpMRI has been integrated into the care of patients on active surveillance and effectively stratifies risk of Gleason ≥3 + 4 prostate cancer in this population.
引用
- Curci NE, Lane BR, Shankar PR, et al. Integration and Diagnostic Accuracy of 3T Nonendorectal coil Prostate Magnetic Resonance Imaging in the Context of Active Surveillance. Urology. 2018. PMID: 29653121. doi:10.1016/j.urology.2018.02.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。